Homepage
Author:
Solid Biosciences Inc.
Posted Date:
April 7, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc.
April 7, 2026
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Solid Biosciences Inc.
March 19, 2026
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
Solid Biosciences Inc.
March 11, 2026
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Solid Biosciences Inc.
March 6, 2026
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
Solid Biosciences Inc.
March 6, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc.
March 2, 2026
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences Inc.
February 9, 2026
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Solid Biosciences Inc.
February 8, 2026
